- BioSapien, a biotech startup based in the UAE and the US, has secured new funding to support clinical trials for cancer treatments.
- The company plans to begin MediChip™ clinical trials for colorectal cancer in the UAE by Q2 2025.
Biotech startup BioSapien has successfully extended its pre-Series A funding round to $7 million. Global Ventures collaborated with Dara Holding to lead this round supporting the company’s mission to transform cancer treatment through innovation.
BioSapien’s innovative approach to cancer treatment is based on its proprietary MediChip™ technology, which uses advanced 3D printing to deliver targeted, localized therapy directly to tumors. This technique reduces the systemic side effects typically associated with conventional treatments
The new funding will support clinical trials in Abu Dhabi, and they will begin in 2025. It will also accelerate product development, and attract new talent.
The startup initially targets colorectal cancer, with plans to expand to pancreatic and lung cancers. It also aims to address non-cancer treatments, such as hormones and biologics.
A survey conducted by the Patient-Centered Dosing Initiative found that 86% of patients reported significant side effects from chemotherapy and 83% of those felt better after a dose reduction. MediChip™ is expected to transform cancer care by minimizing the need for high doses of chemotherapy and improving patient outcomes.
BioSapien’s platform is designed to provide localized, slow-release drug delivery that can be easily attached to tissue. This provides patients with a treatment option that has minimal side effects.
This funding not only helps BioSapien but shows a regional shift in healthcare innovation. With the MENA region investing heavily in digital health, BioSapien’s vision aligns with market trends while addressing patient needs.
If you see something out of place or would like to contribute to this story, check out our Ethics and Policy section.